Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6397-6403

  Asiaf, Asia ^a   Ahmad, Shiekh Tanveer ^b   Aziz, Sheikh Aejaz ^c   Malik, Ajaz Ahmad ^c   Rasool, Zubaida ^c   Masood, Akbar ^a   Zargar, Mohammad Afzal ^a  

^a UNIVERSITY OF KASHMIR   (India)

^b UNIVERSITY OF CALGARY   (Canada)

^c SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

E cadherin; ER; Invasive ductal carcinoma; Kashmir; Promoter methylation

Indexed keywords

CADHERIN; CDH1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BREAST; BREAST TUMOR; CANCER GRADING; CANCER STAGING; DNA METHYLATION; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; INDIA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INDIA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84908369205     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6397     Document Type: Article

References (51)

1. Acs G, Lawton TJ, Rebbeck TR, et al (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Path, 115, 85-98.
2. Andrews JL, Kim AC, Hens JR (2012). The role and function of cadherins in the mammary gland. Breast Cancer Res, 14, 203-13.
3. Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet, 16, 168-74.
4. Berx G, Cleton-Jansen AM, Nollet F, et al (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J, 14, 6107.
5. Brock MV, Gou M, Akiyama Y, et al (2003). Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin cancer res, 9, 2912-9.
6. Caldeira JRF, Prando EC, Quevedo FC, et al (2006). CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC cancer, 6, 48.
7. Cavallaro U, Christofori G (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer, 4, 118-32.
8. Debies MT, Welch DR (2001). Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia, 6, 441-51.
9. Elledge RM, Green S, Pugh R, et al (2000). Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer, 89, 111-7.
10. Fisher B, Redmond C, Brown A, et al (1983). Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol, 1, 227-41.
11. Graff JR, Gabrielson E, Fujii H, et al (2000). Methylation patterns of the E-cadherin 5'-CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem, 275, 2727-32.
12. Graff JR, Herman JG, Lapidus RG, et al (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 55, 5195-9.
13. Hajra KM, Ji X, Fearon ER (1999). Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene, 18.
14. Harvey JM, Clark GM, Osborne CK, et al (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17, 1474-.
15. Hennig G, Lowrick O, Birchmeier W, et al (1996). Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem, 271, 595-602.
16. Hirohashi S (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Path, 153, 333-9.
17. Hu X-C, Loo WTY, Chow LWC (2002). E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life sci, 71, 1397-404.
18. Issa JP, Ahuja N (2000). Aging, methylation and cancer. Histol Histopathol, 15, 835-42.
19. Kanai Y, Oda T, Tsuda H, et al (1994). Point mutation of the ecadherin gene in invasive lobular carcinoma of the breast. Cancer Sci, 85, 1035-9.
20. Kowalski PJ, Rubin MA, Kleer CG (2003). E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res, 5, 217-22.
21. Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80.
22. Lo P-K, Sukumar S (2008). Epigenomics and breast cancer. Pharmacogenomics.
23. Lombaerts M, Middeldorp JW, van der Weide E, et al (2004). Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. Biochem Bioph Res Co, 319, 697-704.
24. Mir MR, Shabir N, Wani KA, et al (2012). Association between p16, hMLH1 and E-cadherin promoter hypermethylation and intake of local hot salted tea and sun-dried foods in Kashmiris with gastric tumors. Asian Pac J Cancer Prev, 13, 181-6.
25. Nass SJ, Herman JG, Gabrielson E, et al (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5 CpG islands increases with malignant progression in human breast cancer. Cancer Res, 60, 4346-8.
26. Oka H, Shiozaki H, Kobayashi K, et al (1992). Correlation between E-cadherin expression and metastasis in human breast cancer: preliminary report. Nihon Geka Gakkai zasshi, 93, 105.
27. Overduin M, Harvey TS, Bagby S, et al (1995). Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science, 267, 386-9.
28. Peinado H, Ballestar E, Esteller M, et al (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol, 24, 306-19.
29. Prasad CP, Mirza S, Sharma G, et al (2008). Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast. Life Sci, 83, 318-25.
30. Raish M, Dhillon VS, Ahmad A, et al (2009). Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol, 2, 264.
31. Ronneberg JA, Fleischer T, Solvang HK, et al Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol, 5, 61-76.
32. Rose C, Andersen K, Mouridsen H, et al (1985). Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. The Lancet, 325, 16-9.
33. Sadot E, Simcha I, Shtutman M, et al (1998). Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA, 95, 15339-44.
34. Sarrio D, Perez-Mies B, Hardisson D, et al (2004). Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 23, 3272-83.
35. Sebova K, Zmetakova I, Bella V, et al (2011). RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Epidemiol Biomarkers Prev, 10, 13-26.
36. Shargh SA, Sakizli M, Farajnia S, et al (2011). Evaluation of methylation pattern in promoter region of E-cadherin gene and its relation to tumor grade and stage in breast cancer. Afr J Biotechnol, 10, 1745-51.
37. Shinozaki M, Hoon DSB, Giuliano AE, et al (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res, 11, 2156-62.
38. Sofi GN, Sofi JN, Nadeem R, et al (2012). Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev, 13, 5047-52.
39. Syeed N, Husain SA, Abdullah S, et al (2010). Caveolin-1 promotes mammary tumorigenesis: mutational profile of the Kashmiri population. Asian Pac J Cancer Prev, 11, 689-96.
40. Szyf M, Pakneshan P, Rabbani SA (2004). DNA methylation and breast cancer. Bioche Pharmacol, 68, 1187-97.
41. Tamura G, Yin J, Wang S, et al (2000). E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst, 92, 569-73.
42. Tao MH, Shields PG, Nie J, et al (2009). DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Tr, 114, 559-68.
43. Valavaara R, Tuominen J, Johansson R (1990). Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer, 66, 2264-9.
44. Vos CB, Cleton-Jansen AM, Berx G, et al (1997). E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer, 76, 1131.
45. Wani SQ, Khan T, Wani SY, et al (2012). Clinicoepidemiological analysis of female breast cancer patients in Kashmir. J Can Res Ther, 8, 389.
46. Xiong H-L, Liu X-Q, Sun A-H, et al (2013). Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev, 14, 3139-42.
47. Yang X, Yan L, Davidson NE (2001). DNA methylation in breast cancer. Endocr-Relat Cancer, 8, 115-27.
48. Yoder BJ, Wilkinson EJ, Massoll NA (2007). Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J, 13, 172-9.
49. Yoshida R, Kimura N, Harada Y, et al (2001). The loss of E-cadherin, a and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol, 18, 513.
50. Yuan Y-L, Wang Y-M, Liu H, et al (2012). Aberrant expression of e-cadherin in lung tissues of patients with probable lung cancer. Asian Pac J Cancer Prev, 13, 5149-53.
51. Zheng, Shi-Ying, Hou, et al (2012). Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer. Asian Pac J Cancer Prev, 13, 1557-61.